Iterum Therapeutics PLC(ITRM)stock report

Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The Company is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The Company is developing sulopenem – the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. It is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. It has demonstrated potent in vitro activity against all genera of Enterobacteriacease, in anaerobes such as Bacteroides, Prevotella, Porphyromonas, Fusobacterium and Peptostreptococcus, gram-positive organisms including methicillin-susceptible staphylococci, Streptococcus pyogenes and Streptococcus pneumonia.

Market Cap:70.6M; Shares Outstanding:14.9M; Q3 2019(9/30/19): Cash 28.88M. Loss 31.27M

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -8.82 94.84% -18.87%
2019.3.31 -1.44 97.65% -83.67%
2019.6.30 -3.37 49.85% -134.03%
2019.9.30 -5.52 25.61% -63.80%



Insider Transactions:

Institution Ownership:

Total institutions: 20,no change
Shares hold: 5976.9k shares. no change
shares% hold: 40.20%,no change

Analyst Ratings:

Leave a Reply